Skip to main content
Caplight Logo









Intervene Immune

Intervene Immune

Private
Torrance, CaliforniaHealthcare & Life Scienceshttps://interveneimmune.com/

Last Round

Seed

Dec 27, 2019

Total Funding Raised

$471,000

Company Overview

Intervene Immune is a biotechnology company that develops immuno-therapies and diagnostics designed for thymus regeneration and age-related immune system decline.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2C

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

thymus regenerationimmunosenescence reversallongevity biotechcombination therapyage reversalimmune restorationepigenetic aging reversalhealthspan extensionanti-aging therapyclinical trialsdrug repurposingpay-to-participate trialpersonalized dosing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Intervene Immune Comparables

Compare Intervene Immune with similar companies based on industry and business-model similarity.

Intervene Immune comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TECregen
77%
United Therapeutics
77%
Tolerance Bio, Inc.
68%

Intervene Immune Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedDec 27, 2019

Intervene Immune Investors

Notable investors and investment history

Intervene Immune investors
InvestorRounds
Longevitytech.fundSeed
quadraScope VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 27, 2019

    $471K raised from Longevitytech.fund and quadraScope Ventures.

Intervene Immune Filings

Explore SEC and related filing metadata, where available.

Intervene Immune filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Intervene Immune's valuation, stock price, and market status.

Is Intervene Immune a public or private company?

Intervene Immune is a private company.

What is the current stock price of Intervene Immune?

Intervene Immune is a private company with no public stock price. No recent secondary market data is available.

How much is Intervene Immune worth (valuation)?

Valuation information for Intervene Immune is not publicly available.

Can I buy Intervene Immune stock?

Intervene Immune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Intervene Immune's last funding round?

Intervene Immune's most recent funding round was Seed on December 27, 2019.

Who are the main investors in Intervene Immune?

Key investors in Intervene Immune include Longevitytech.fund, quadraScope Ventures.

Will Intervene Immune IPO soon?

No public IPO plans have been announced for Intervene Immune.

How can I track Intervene Immune secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Intervene Immune's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTorrance, California
Year Founded2013
Last FundingDec 27, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?